WordNet

travel or traverse (a distance); "This car does 150 miles per hour"; "We did 6 miles on our hike every day"
the syllable naming the first (tonic) note of any major scale in solmization (同)doh, ut
proceed or get along; "How is she doing in her new job?"; "How are you making out in graduate school?"; "Hes come a long way" (同)fare, make_out, come, get along
create or design, often in a certain way; "Do my room in blue"; "I did this piece in wood to express my love for the forest" (同)make
carry on or function; "We could do with a little more help around here" (同)manage
get (something) done; "I did my job" (同)perform
treat with an agent; add (an agent) to; "The ray dosed the paint"
the quantity of an active agent (substance or radiation) taken in or absorbed at any one time (同)dosage
a measured portion of medicine taken at any one time (同)dosage
relating to or situated in or extending toward the middle (同)medial
the value below which 50% of the cases fall (同)median value
relating to or constituting the middle value of an ordered set of values (or the average of the middle two in a set with an even number of values); "the median value of 17, 20, and 36 is 20"; "the median income for the year was $15,000" (同)average
of or relating to or caused by a toxin or poison; "suffering from exposure to toxic substances"

PrepTutorEJDIC

touchdown; touchdowns / Treasury Department
《疑問文・否定文を作る》 / 《否定命令文を作る》 / 《助動詞とbe動詞のどちらも含まない文に用いて付加疑問を作る》 / 《強意語として》 / 《文》《助動詞とbe動詞のどちらも含まない文に用いて倒置文を作る》 / 《あいづちを打つ場合に》 / 《先行する動詞またはそれを含む述部の代用》 / 《so,nor,neitherで始まる簡略文で》 / …‘を'『する』,行う,果たす / 《通例have done,時にbe doneの形で》…‘を'『終える』,済ませる / …‘を'作る,作り出す / …‘を'『処理する』,整える,片付ける / 〈学課〉‘を'『勉強する』,専攻する / 〈利益・害など〉‘を'与える,もたらす / 〈人〉‘に'『役立つ』,用が足りる(serve) / …の速度で進む,距離を行く / …‘を'見物する / 〈劇〉‘を'上演する;…‘の'役を演じる / …の役目(仕事)をする / 《おもに英》…‘を'だます,かつぐ / 《話》…をへとへとにさせる / 『する』;活動する / 《通例have done,時にbe doneの形で》(…を)『終える』,済ます《+『with』+『名』》 / 〈事が〉『運ぶ』;〈人が〉暮らしていく,健康である / 〈物が〉(…に)『間に合う』,十分である;〈人が〉(…に)役に立つ,向く《+『for』+『名』》 / 《複数形で》すべきこと / 〈C〉《おもに英》大宴会,大パーティー / 〈C〉《英話》詐欺,ぺてん
ド(全音階の第1音)
(おもに飲み薬1回分の)『服用量』 / (痛いこと・いやなことの)1回分,一定量 / (人などが受ける放射線の)線量 / 性病 / (…を)…‘に'投薬する,服用させる《+『名』+『with』+『名』》
中央の,中間の / 中間数の,中央値の / (統計・数学で)中間数,中央値;中点
毒性の,有毒な / 毒による
mediumの複数形

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2012/12/01 15:05:33」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. Carpal tunnel syndrome: Treatment and prognosis
2. 再発性または難治性の慢性リンパ性白血病の治療 treatment of relapsed or refractory chronic lymphocytic leukemia
3. 腕神経叢症候群 brachial plexus syndromes
4. 限局期（I/II）濾胞性リンパ腫の初期治療 initial treatment of limited stage i ii follicular lymphoma
5. 進行性胆管癌に対する全身療法 systemic therapy for advanced cholangiocarcinoma

English Journal

Feasibility of two schedules of weekly paclitaxel in HER2-negative early breast cancer in a Brazilian community setting.

Santana IA1, Oliveira JA2, da Silva Lima JM2, Testa L2, Piato JR2, Hoff PM2, Mano MS2.
Breast cancer (Tokyo, Japan).Breast Cancer.2016 Mar;23(2):261-5. doi: 10.1007/s12282-014-0564-9. Epub 2014 Sep 19.
BACKGROUND: Weekly paclitaxel has been shown more effective and less toxic than the conventional three-weekly administration. The GEICAM 9906 demonstrated effectiveness and safety of a dose-dense schedule of 100 mg/m(2) of paclitaxel given over 8 weeks (w). This schedule has been adopted at our in
PMID 25234137

Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients.

Takahashi K1, Kantarjian H2, Garcia-Manero G2, Borthakur G2, Kadia T2, DiNardo C2, Jabbour E2, Pierce S2, Estrov Z2, Konopleva M2, Andreeff M2, Ravandi F2, Cortes J3.
Clinical lymphoma, myeloma & leukemia.Clin Lymphoma Myeloma Leuk.2016 Mar;16(3):163-168.e2. doi: 10.1016/j.clml.2015.11.016. Epub 2015 Nov 24.
INTRODUCTION: Most patients with acute myeloid leukemia (AML) age ≥ 60 years are not offered intensive induction because of high mortality. Phase 2 studies of clofarabine plus low-dose cytarabine (CLDA) as frontline therapy for elderly AML patients demonstrated high response and acceptable toxici
PMID 26752456

TLc-A, the leading nanochelating-based nanochelator, reduces iron overload in vitro and in vivo.

Kalanaky S1, Hafizi M1,2, Safari S1, Mousavizadeh K3, Kabiri M4, Farsinejad A5, Fakharzadeh S6, Nazaran MH7.
International journal of hematology.Int J Hematol.2016 Mar;103(3):274-82. doi: 10.1007/s12185-015-1932-8. Epub 2016 Feb 1.
Iron chelation therapy is an effective approach to the treatment of iron overload conditions, in which iron builds up to toxic levels in the body and may cause organ damage. Treatments using deferoxamine, deferasirox and deferiprone have been introduced and despite their disadvantages, they remain t
PMID 26830968

Japanese Journal

In vitro and in vivo characteristics of core–shell type nanogel particles: Optimization of core cross-linking density and surface poly(ethylene glycol) density in PEGylated nanogels

Tamura Masato,Ichinohe Satoshi,Tamura Atsushi,Ikeda Yutaka,Nagasaki Yukio,田村磨聖,長崎幸夫
Acta Biomaterialia 7(9), 3354-3361, 2011-09
… The toxic effect of the PEGylated nanogels derived from polyamine gel cores was significantly reduced when the cross-linking density was increased, and those with a cross-linking density of 5 mol.% showed a remarkably high median lethal dose (LD50) value >200 mg kg−1,despite the abundance of amino groups in the core. …
NAID 120003339037

基礎研究を基盤とした至適抗癌剤併用療法の構築

藤秀人
医療薬学 33(11), 897-904, 2007-11-10
… Metastatic breast cancer (MBC) is almost always incurable and median survival is 18-24 months. … Although the combination of adriamycin (ADR) and docetaxel (DOC) has demonstrated higher efficacy against MBC, severe myelosuppression and cardiotoxicity have been dose-limiting factors. … In the DOC-ADR group, as compared to the ADR/DOC group, in addition to there being significantly less leukopenia and toxic death, the tumor growth inhibition rate was significantly higher. …
NAID 110006452666